FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD.
Alzheimer's disease
Cingulate island sign
Demenia with Lewy bodies
FDG PET
Mild cognitive impairment
Journal
NeuroImage. Clinical
ISSN: 2213-1582
Titre abrégé: Neuroimage Clin
Pays: Netherlands
ID NLM: 101597070
Informations de publication
Date de publication:
2021
2021
Historique:
received:
10
02
2021
revised:
29
06
2021
accepted:
30
06
2021
pubmed:
13
7
2021
medline:
14
9
2021
entrez:
12
7
2021
Statut:
ppublish
Résumé
Patients with dementia with Lewy bodies (DLB) are characterized by hypometabolism in the parieto-occipital cortex and the cingulate island sign (CIS) on Patients with MCI from the Mayo Clinic Alzheimer's Disease Research Center who underwent FDG PET at baseline and progressed to either probable DLB (MCI-DLB; n = 17) or AD dementia (MCI-AD; n = 41) during follow-up, and a comparison cohort of CU controls (n = 100) were included. Patients with MCI-DLB had hypometabolism in the parieto-occipital cortex extending into temporal lobes, substantia nigra and thalamus. When compared to MCI-AD, medial temporal and posterior cingulate metabolism were preserved in patients with MCI-DLB, accompanied by greater hypometabolism in the substantia nigra in MCI-DLB compared to MCI-AD. In distinguishing MCI-DLB from MCI-AD at the maximum value of Youden's index, CIS ratio was highly specific (90%) but not sensitive (59%), but a higher medial temporal to substantia nigra ratio was both sensitive (94%) and specific (83%). FDG PET is a potential biomarker for the prodromal stage of DLB. A higher medial temporal metabolism and CIS ratio, and lower substantia nigra metabolism have additive value in distinguishing prodromal DLB and AD.
Sections du résumé
BACKGROUND AND PURPOSE
Patients with dementia with Lewy bodies (DLB) are characterized by hypometabolism in the parieto-occipital cortex and the cingulate island sign (CIS) on
METHODS
Patients with MCI from the Mayo Clinic Alzheimer's Disease Research Center who underwent FDG PET at baseline and progressed to either probable DLB (MCI-DLB; n = 17) or AD dementia (MCI-AD; n = 41) during follow-up, and a comparison cohort of CU controls (n = 100) were included.
RESULTS
Patients with MCI-DLB had hypometabolism in the parieto-occipital cortex extending into temporal lobes, substantia nigra and thalamus. When compared to MCI-AD, medial temporal and posterior cingulate metabolism were preserved in patients with MCI-DLB, accompanied by greater hypometabolism in the substantia nigra in MCI-DLB compared to MCI-AD. In distinguishing MCI-DLB from MCI-AD at the maximum value of Youden's index, CIS ratio was highly specific (90%) but not sensitive (59%), but a higher medial temporal to substantia nigra ratio was both sensitive (94%) and specific (83%).
CONCLUSION
FDG PET is a potential biomarker for the prodromal stage of DLB. A higher medial temporal metabolism and CIS ratio, and lower substantia nigra metabolism have additive value in distinguishing prodromal DLB and AD.
Identifiants
pubmed: 34252877
pii: S2213-1582(21)00198-4
doi: 10.1016/j.nicl.2021.102754
pmc: PMC8278422
pii:
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
102754Subventions
Organisme : NIA NIH HHS
ID : R01 AG011378
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS100620
Pays : United States
Organisme : NCRR NIH HHS
ID : C06 RR018898
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG016574
Pays : United States
Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Références
Neurology. 2017 Jul 4;89(1):88-100
pubmed: 28592453
Neurology. 2012 Aug 7;79(6):553-60
pubmed: 22843258
Psychol Med. 2019 Feb;49(3):396-402
pubmed: 29692275
J Intern Med. 2004 Sep;256(3):183-94
pubmed: 15324362
Neurosci Lett. 1997 Oct 10;235(1-2):49-52
pubmed: 9389593
Neuroimage. 2018 Apr 15;170:271-282
pubmed: 28536045
AJNR Am J Neuroradiol. 2010 Aug;31(7):1247-53
pubmed: 20299441
J Nucl Med. 2009 Oct;50(10):1638-45
pubmed: 19759102
Neurology. 2020 Apr 28;94(17):743-755
pubmed: 32241955
Brain Commun. 2020;2(1):fcaa040
pubmed: 32566926
Neurobiol Aging. 2019 Apr;76:9-17
pubmed: 30611093
Mov Disord. 2016 Jul;31(7):989-94
pubmed: 27214825
Neurology. 2014 Aug 26;83(9):801-9
pubmed: 25056580
J Nucl Med. 2008 Mar;49(3):390-8
pubmed: 18287270
Alzheimers Dement. 2019 Mar;15(3):400-409
pubmed: 30439333
Ann Neurol. 2013 Aug;74(2):199-208
pubmed: 23686697
Neurology. 1996 Aug;47(2):462-6
pubmed: 8757021
Parkinsonism Relat Disord. 2019 Jul;64:300-303
pubmed: 30905401
Neuroepidemiology. 2008;30(1):58-69
pubmed: 18259084
Neurology. 2004 Jan 27;62(2):181-7
pubmed: 14745051
Neurology. 2020 Jan 21;94(3):e282-e291
pubmed: 31862783
Neurology. 1998 Jul;51(1):125-30
pubmed: 9674790
J Neurosci. 2008 Jun 11;28(24):6174-81
pubmed: 18550759
Neurobiol Aging. 2012 Sep;33(9):2091-105
pubmed: 22018896
J Nucl Med. 2005 Jun;46(6):936-44
pubmed: 15937303
Neurology. 2012 Jan 31;78(5):342-51
pubmed: 22282647
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S41-4
pubmed: 22166451
Neurology. 2010 Jun 1;74(22):1814-21
pubmed: 20513818
Brain. 2020 Mar 1;143(3):944-959
pubmed: 32057084
Neurology. 2016 Nov 29;87(22):2317-2323
pubmed: 27807186